REFERENCES
- Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler W.C., Jr., Clarke-Pearson D.L., Liao S.Y. Randomized Comparison of Fluorouracil Plus Cisplatin Versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB–IVA Carcinoma of the Cervix with Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study. J. Clin. Oncol. 1999; 17(5)1339–1348
- Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., Clarke-Pearson D.L., Insalaco S. Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer. N. Engl. J. Med. 1999; 340(15)1144–1153
- Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs C.L., 3rd, Walker J.L., Gersell D. Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma. N. Engl. J. Med. 1999; 340(15)1154–1161
- Park R.C., Blom J., Disaia P.J., Lagasse L.D., Blessing J.A. Treatment of Women with Disseminated or Recurrent Advanced Ovarian Cancer with Melphalan Alone in Combination with 5-Fluorouracil and Dactinomycin or with the Combination of Cytoxan, 5-Fluorouracil and Dactinomycin. Cancer 1980; 45(10)2529–2542
- Omura G.A., Morrow C.P., Blessing J.A., Miller A., Buchsbaum H.J., Homesley H.D., Leone L. A Randomized Comparison of Melphalan Versus Melphalan Plus Hexamethylmelamine Versus Doxorubicin Plus Cyclophosphamide in Ovarian Carcinoma. Cancer 1983; 51(5)783–789
- Omura G., Blessing J.A., Ehrlich C.E., Miller A., Yordan E., Creasman W.T., Homesley H.D. A Randomized Trial of Cyclophosphamide and Doxorubicin with or without Cisplatin in Advanced Ovarian Carcinoma. A Gynecologic Oncology Group Study. Cancer 1986; 57(9)1725–1730
- McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer. N. Engl. J. Med. 1996; 334(1)1–6